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The purpose of this study was to assess the influence of single-nucleotide polymorphisms (SNPs) on cytokine genes in the
development of diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients and 221 controls were investigated.
Among them, 97 patients treated with R-CHOP were subdivided into two groups: (i) complete remission of the disease and (ii)
patients who progressed to death, relapsed, or had disease progression. The SNPs investigated by PCR-SSP were TNF -308G>A
(rs1800629), IFNG +874A>T (rs2430561), IL6 -174G>C (rs1800795), IL10 -1082A>G (rs1800896), IL10 -819C>T (rs1800871),
IL10 -592C>A (rs1800872), and TGFB1 codon10T>C (rs1982073) and codon25G>C (rs1800471). In general, the genotypes that
have been associated in the literature with lower production or intermediate production of IL-10 and higher production of
IFN-γ were associated with the protection of the development of the disease, possibly favoring the Th1 immune response
and diminishing the capacity of cell proliferation. However, patients receiving R-CHOP treatment presented unfavorable
prognoses in the presence of genotypes related to the intermediate production of IL-10 and high production of TGF-β1,
indicating that cytokines may be related to the response to treatment and action mechanisms of Rituximab.
1. Introduction
Diffuse large B-cell lymphoma (DLBCL) is considered a rare
disease, affecting 1-5/10,000 individuals [1], and it is the most
common type of non-Hodgkin’s lymphoma (NHL). Many
cases of DLBCL do not have a definite etiology, but the dis-
ease is frequently reported in individuals with autoimmune
diseases and acquired immune deficiency or in immunosup-
pressed patients [2], evidencing the importance of the
immune response in this type of lymphoma.
Studies have suggested that immunosuppression and
inhibition of Th1 responses are related to the risk of develop-
ing lymphomas [3, 4], and several single-nucleotide poly-
morphisms (SNPs) in cytokine genes have been associated
with a higher or lower risk of developing B-cell lymphomas
[3, 5–7].
Secretion of certain cytokines from tumor cells, particu-
larly interleukin- (IL-) 6, IL-10, and TNF-α, renders them
resistant to the cytotoxic effects of chemotherapeutic drugs.
The inclusion of Rituximab in the treatment composed of
Cyclophosphamide, Doxorubicin, Vincristine, and Predni-
sone (R-CHOP) greatly improved the chemotherapy
response and survival of the DLBCL patients. However,
not all patients respond in the same way to the treatment,
and the action mechanisms of Rituximab are not fully
understood [8–10].
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Some authors have shown that polymorphisms in
cytokine genes may influence the development of DLBCL,
while other researchers have been struggling to find bio-
markers that can serve as prognosis and predictors, not only
to identify patients who will undergo a particularly aggressive
course but also to select with accuracy the most beneficial
therapeutic treatment for each patient [8–11].
In this context, the purpose of the present study was to
evaluate the influence of polymorphisms on cytokine genes
in the development of DLBCL and in the prognosis of
patients treated with R-CHOP.
2. Materials and Methods
2.1. Ethical Aspects. The research was approved by the Ethics
in Research Committee involving human beings from the
State University of Campinas (UNICAMP No. 1117/2009)
attending the Helsinki Declaration of 1975, as revised in
2008. All participants signed a free and informed consent
form.
2.2. Characterization of Patients and Controls. From April
2009 to June 2013, 112 patients with DLBCL were selected
from Campinas and region (22°54′S and 47°03′W) and
treated at the State University of Campinas in the Hematol-
ogy and Hemotherapy Center (CHH-UNICAMP). Clinical
and epidemiological data, including age, gender, ECOG
(Eastern Cooperative Oncology Group), IPI (International
Progression Index), Ann Arbor staging, type of treatment,
nodal involvement, LDH (lactate dehydrogenase) levels,
bone marrow involvement, and subtype lymphomas, were
obtained from each patient’s medical records.
The diagnosis of large B-cell non-Hodgkin lymphoma
was performed through histopathological examination of
the affected lymph node or biopsy of the tumor mass, and
the classification of the lymphoma subtype was performed
through an immunohistochemical evaluation, as classified
by the World Health Organization [12]. The initial staging
of patients with lymphoma was performed based on the clin-
ical history and physical examination, as well as on the results
obtained from the imaging exams: computed tomography of
the chest and abdomen or chest X-ray and abdominal ultra-
sound and bone marrow biopsy. Patients were monitored
during the treatment and posttreatment period with regu-
larly scheduled clinical and radiographic exams. Of the total
number of patients, 101 were treated with the R-CHOP treat-
ment (Rituximab, Cyclophosphamide, Doxorubicin, Vincris-
tine, and Prednisone of 4 to 8 cycles, depending on
lymphoma staging). Patients were divided into groups
according to their response to treatment: Those with normal-
ization of physical and radiological findings four weeks after
the last cycle of chemotherapy were considered as patients in
complete remission. Those with a reduction of 50% of the ini-
tial tumor mass were defined as patients in partial remission,
and those who did not present the above criteria were consid-
ered nonresponders.
The control group consisted of 221 voluntary donors of
blood and bone marrow registered at CHH-UNICAMP from
the same region as patients with DLBCL. Pairing was done
according to gender.
2.3. DNA Extraction and Cytokine Genotyping. Blood
samples from each individual were collected in EDTA tubes,
and the respective DNAs were extracted using the DNA
blood mini kit (QIAamp, Qiagen, Mississauga, Canada),
following the manufacturer’s recommendations.
Eight SNPs were investigated by Polymerase Chain
Reaction-Single Specific Primer (PCR-SSP): TNF -308G>A
(rs1800629), IFNG +874A>T (rs2430561), IL6 -174G>C
(rs1800795), IL10 -1082A>G (rs1800896), IL10 -819C>T
(rs1800871), IL10 -592C>A (rs1800872) and TGFB1
codon10T>C (rs1982073) and codon25G>C (rs1800471),
using the commercial cytokine genotyping kit (One Lambda,
Canoga Park, CA, USA), following the manufacturer’s
recommendations. The integrity of the reaction was evalu-
ated by a pair of primers as the internal control. Standard
forms supplied by the manufacturer were used for the
interpretation.
2.4. Statistical Analyses. The SNPStats web tool, available at
https://www.snpstats.net/start.htm, was used to perform sta-
tistical analyses [13]. Genotype and haplotype frequencies
were calculated in patient and control samples, and the
Hardy-Weinberg equilibrium was evaluated from the geno-
type distribution analysis. The haplotype frequencies were
estimated using the implementation of the expectation-
maximization (EM) algorithm coded into the haplo.stats
package [13] and were performed for the IL10 and TGFB1
genes. A logistic regression test, adjusted for age and gender,
was used to verify the association of SNPs in cytokine genes
and the development of DLBCL, as well as to evaluate the
association of these SNPs in the progression of the disease
in individuals treated with R-CHOP. Association tests were
performed for codominant, dominant, recessive, overdomi-
nant, and log-additive genetic inheritance models. The best
inheritance model was chosen according to the lowest Akaike
information criterion (AIC). To assess the association of
SNPs in the genes studied in the progression of DLBCL,
patients treated with R-CHOP were divided into two groups:
one group composed of patients who had complete disease
remission (control) and the other group with patients who
died or had recurrence or progression of the disease. It was
also analyzed whether polymorphisms in the cytokine genes
influenced in clinical staging (advanced stages of disease ver-
sus nonadvanced stages), LDH (normal versus augmented),
and IPI (low and intermediate-low versus intermediate-
high and high). Contingency tables were constructed, and
the chi-squared test was performed to analyze the combined
effect between SNPs in different cytokines, with Yates correc-
tion when necessary. The odds ratio (OR) was calculated
considering a 95% confidence interval, and results were con-
sidered significant with P < 0:05. The Bonferroni adjustment
for multiple testing was not applied because all variants
analyzed have been associated with DLBCL in any other
populations.
The influence of cytokine genes and the IL10 ACC
haplotype were also investigated on the clinical evolution of
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DLBCL based on the overall survival and progression-free
survival analyses with the Kaplan-Meier estimator. Cox uni-
variate models were used to determine the statistical signifi-
cance (P values of the methods: “likelihood,” “Wald,” and
“log-rank”) and the cytokine gene relative risks (RR) with
confidence intervals (CI) of 95%, besides other variables as
age, gender, LDH, disease stages, IPI, and response to treat-
ment. Factors associated with the risk of progression and
death with 20% significance were examined using Cox multi-
variate analysis. Analyses were conducted with statistical
package “R” version 4.0.2. for Windows program [14].
3. Results
3.1. Characteristics of Patients and Controls. The characteris-
tics of patients and controls are described in Table 1. The
mean age of the patients and controls was 60.4 years and
50.6 years, respectively. The majority of the patients were
more than 60 years of age, while the majority of the controls
were younger than 60 years old (P ≤ 0:05).
Of the 101 patients treated with the R-CHOP, 72 (71.2%)
presented complete remission, 17 (16.8%) died, four (4.0%)
relapsed, four (4.0%) presented disease progression, and four
(4.0%) patients were lost to follow-up (Table 1).
Patients were followed up until October 2013. The
median time for overall survival was 17 months (1-54
months), and for progression-free survival, it was 16.9
months (1-54 months).
3.2. Genotype and Haplotype Frequency Distributions in
Patients and Controls. The distribution of observed and
expected genotype frequencies for all genes analyzed was in
Hardy-Weinberg equilibrium (P > 0:05).
The distribution of the genotype and haplotype fre-
quencies of the studied cytokine genes in patients with
DLBCL and controls is showed in Table 2. Significant dif-
ferences were not observed for most of analyzed SNPs
between DLBCL patients and controls. However, for IL10
-819 and IL10 -592, higher genotype frequencies of the var-
iants were observed in patients when compared to controls.
The choice inheritance model was the dominant where a
single copy of the mutant allele is sufficient to modify the
risk. Through this model, the genotypes C/T or T/T and
C/A or A/A of the IL10 -819 and IL10 -592, respectively,
are indicated to be a risk factor for the development of
DLBCL in relation to the C/C genotypes of both SNPs
(OR: 2.23, P = 0:013). On the other hand, the IFNG +874
T/T or A/T genotype frequencies were less frequent in
patients than controls (OR: 0.35, P < 0:001) and, also, in a
Table 1: Clinical and epidemiological characteristics of patients with diffuse large B-cell non-Hodgkin’s lymphoma (N = 112) and controls
(N = 221).
Characteristics Patients Controls P
Age (mean ± standard deviation) 60:4 ± 15:4 50:6 ± 8:0 0.01
Gender n (%)
Female 57 (50.9) 109 (49.3) NS
Male 55 (49.1) 112 (50.7) NS







Low and intermediate-low 70 (62.5)





Not treated 3 (2.7)
Response to treatment with R-CHOP n (%)
Complete remission 72 (71.2)
Progression of disease 4 (4.0)
Relapse 4 (4.0)
Death 17 (16.8)
Lost to follow-up 4 (4.0)
NS = not significant; LDH= lactate dehydrogenase; IPI = international prognosis index; R-CHOP =Rituximab—Cyclophosphamide, Doxorubicin, Vincristine,
and Prednisone.
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dominant inheritance model. The statistical power of the
test was on average 88%, ranging from 75 to 97%.
The presence of IL10 polymorphisms (-819C>T and
-592C>A) indicated risk for the development of DLBCL,
and the presence of IFNG polymorphism (+874A>T) indi-
cated protection. The individuals that presented three geno-
types (C/T or T/T and C/A or A/A of the IL10 -819 and
IL10 -592, respectively, and the A/A of the IFNG +874) that
could favor the development of the disease were grouped
and compared with the individuals that did not have these
three genotypes together. For this combined analysis, these
two IL10 SNPs were being counted as a single one, since they
are in strong linkage disequilibrium (D′ = 0, 99). It was
observed that the risk of developing DLBCL in individuals
who had all the three genotypes was higher (OR = 3:98, CI:
2.29-6.14, P ≤ 0:01) than when assessing the individual risk
of each SNP.
In the R-CHOP-treated patients, considering the progno-
sis of the disease, the TGFB1 codon10 T/C genotype fre-
quency was higher in patients who died or had recurrence
or progression of the disease compared to patients with com-
plete remission of disease (OR: 2.39, P = 0:03, overdominant
inheritance model). In the overdominant inheritance model,
heterozygous alleles are compared to a pool of both homozy-
gous alleles. The other SNPs studied did not influence the
prognosis of the treated patients (Table 3).
In addition to these results, the distribution of the haplo-
type frequencies of IL10 and TGFB1 was analyzed consider-
ing the development of DLBCL and the prognosis of the
disease in patients treated with R-CHOP, and the results
are shown in Tables 2 and 3, respectively. According to
TGFB1, there were no differences in the haplotype frequency
distributions when the development of DLBCL or prognosis
of the disease were considered. However, the haplotype IL10
-1082, -819, and -592 ACC was more frequent in controls
compared to DLBCL patients (OR: 0.55, P = 0:03; compared
to the ATA haplotype), and it was less frequent in patients
treated with R-CHOP with complete remission of disease
compared to patients who died or had recurrence or progres-
sion of the disease to progress to death (OR: 2.83, P = 0:03;
compared to the ATA haplotype). The SNPs investigated
did not influence the clinical staging of patients considering
LDH concentration or IPI.
3.3. Analysis of Overall Survival and Progression-Free
Survival. For the IL10 -1082 polymorphism, patients with
the G/G genotype presented greater progression-free survival
than the G/A and A/A genotypes (Figure 1). The other poly-
morphisms, as well as the presence or absence of the haplo-
type ACC of IL10, had no impact on the clinical evolution
of DLBCL based on global and progression-free survival, as
well as on the therapeutic response in the univariate and mul-
tivariate Cox analyses.
4. Discussion
In the present study, we analyzed the possible associations of
polymorphisms in cytokine gene representative of Th1 and
Th2 immune responses, including TNF -308, IFNG +874,
IL6 -174, IL10 -1082, IL10 -819, IL10 -592, and TGFB1
codon10 and TGFB1 codon25, with the development of
DLBCL and progression of the disease in patients treated
with R-CHOP. We found that the C/T or T/T and C/A or
A/A genotypes of IL10 -819 and IL10 -592, respectively,
increased 1.23 times the risk of developing DLBCL in relation
to the patients that had the C/C genotypes in the both SNPs.
On the other hand, the T/T or T/A genotypes of IFNG +874
could be a protective factor in the development of the disease
in relation to the A/A genotype. We also observed the associ-
ation of the ACC haplotype (IL10 -1082, -819, and -592) of
IL10 as a protective factor for the development of the disease
and a risk factor for patients treated with R-CHOP to evolve
to death or have relapse or disease progression. With regard
to patients treated with R-CHOP, the presence of the TGFB1
codon10T/C genotype increased 1.39 times the chance of dis-
ease progression, recurrence, or death, compared to patients
with T/T or C/C genotypes. The genotype associations
between cases and controls were strong, since generally a sta-
tistical power of 80% ensures a high probability of observing
a certain effect. However, the statistical power observed in the
associations involving only treated patients was considered
low, probably because the number of the subjects in each
groups was small and more studies should be performed with
more patients.
Polymorphisms in promoter and regulatory regions of
cytokine genes have been related to the production and
expression of various cytokines [5, 15–18]. In addition, some
polymorphisms have been associated with the development
or progression of DLBCL [5, 7, 10].
Interleukin-10 is a cytokine with a strong immunosup-
pressive effect, because it inhibits the proinflammatory action
of Th1 lymphocytes [19] and may favor tumor growth
in vitro by stimulating cell proliferation and inhibiting apo-
ptosis [18]. The role of polymorphisms in the IL10 gene
and its influence on cytokine levels are controversial. The
absence of the A-allele in the position -1082 was associated,
in vitro, with elevated levels of the cytokine independent of
polymorphisms at other positions of the gene [15]. However,
in another study with DLBCL patients, the frequencies of the
T (IL10 -819) and A (IL10 -592) alleles were shown to be
lower in patients with high levels of IL-10 [4]. In our study,
the haplotype ACC (IL10 -1082, -819, and -592) was a pro-
tective factor for the development of the disease but was asso-
ciated with worse prognosis in patients treated with the R-
CHOP regimen when compared to the ATA haplotype. Liu
et al. [10] found lower progression-free survival in patients
with DLBCL treated with R-CHOP who had this same
ACC haplotype when compared to patients who did not.
Although in our study the haplotype ACC of IL10 did not
influence the overall or progression-free survival, we
observed an association of the genotype G/G (IL10 -1082)
with greater progression-free survival. These results are sim-
ilar to those observed by Lech-Maranda et al. [5], who found
an association between the genotypes G/G and G/A, in this
same position, with better overall survival and better com-
plete remission rate in patients with DLBCL. In this study,
we also observed that the C/C genotypes of IL10 -819 and
IL10 -592 were more frequent in controls compared to
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DLBCL patients, indicating that it was a protective factor.
These results are consistent with those observed in relation
to the ACC haplotype, which was a protective factor for the
development of the disease in relation to the ATA haplotype.
This perhaps indicates that polymorphisms in the IL10 -819
and IL10 -592 regions are likely to be more important factors
in the development of DLBCL.
Interferon-γ is considered one of the main endogenous
immunoregulators, acting mainly as a proinflammatory cyto-
kine [20]. In the present study, it was demonstrated that the
IFNG +874 polymorphism seems to have an impact on the
development of DLBCL, since the T/T and T/A genotypes
were protective factors in relation to the A/A genotype which
is considered a low producer of this cytokine [21, 22]. This
result is similar to another study in which the A/A genotype
was related to the increased risk of developing posttransplant
lymphoproliferative disorders [23]. The risk of developing
DLBCL was even higher when comparing individuals with
three risk genotypes (C/T or T/T and C/A or A/A of the
IL10 -819 and IL10 -592, respectively, and the A/A of the
IFNG +874) to those with only two, one or none of these
genotypes. This is probably related to lower proinflammatory
Table 3: Distribution of genotype frequencies in cytokine genes and in the haplotype frequencies of IL10 and TGFB1 in patients treated with
R-CHOP and considering the prognosis of the disease.
Genotypes
Frequency












G/G 23 (92.0) 52 (72.2)




T/T-C/C 4 (16.0) 20 (27.8) 1.00




G/G 19 (76.0) 64 (88.9)
G/C 5 (20.0) 8 (11.1) NS
C/C 1 (4.0) 0 (0)
IL10 -1082A>G
rs1800896
A/A 13 (52.0) 28 (38.9)
G/A 12 (48.0) 37 (51.4) NS
G/G 0 (0) 7 (9.7)
IL10 -819C>T
rs1800871
C/C 9 (36.0) 23 (31.9)
C/T 14 (56.0) 37 (51.4) NS
T/T 2 (8.0) 12 (16.7)
IL10 -592C>A
rs1800872
C/C 9 (36.0) 23 (31.9)
C/A 14 (56.0) 37 (51.4) NS
A/A 2 (8.0) 12 (16.7)
IL6 -174G>C
rs1800795
G/G 12 (48.0) 40 (55.6)
G/C 11 (44.0) 23 (31.9) NS
C/C 2 (8.0) 9 (12.5)
IFNG +874A>T
rs2430561
A/A 11 (44.0) 36 (50.0)
A/T 9 (36.0) 26 (36.1) NS




ATA 0.360 0.424 1
GCC 0.240 0.354 NS
ACC 0.400 0.222 2.83 (1.11-7.18) 0.03
TGFB1
codon10, codon25
TG 0.510 0.500 1
CG 0.434 0.360 NS
CC 0.045 0.140 NS
TC 0.001 0 NS
NS: not significant; N : population size; n: number of individuals with the allele or genotype; %: genotype and haplotype frequencies × 100; P: P value (adjusted
by age and gender); OR: odds ratio; CI: confidence interval. ∗Best model: overdominant—heterozygous alleles are compared to a pool of both homozygous
alleles. The best inheritance model was chosen according to the lowest Akaike information criterion (AIC).
6 Journal of Immunology Research
cytokine production levels (assigned to A/A of the IFNG
+874) and IL-10 (anti-inflammatory) production levels,
causing a summing effect, increasing the risk of developing
the disease. However, further studies need to be done to bet-
ter understand the association between genotypes and level
production and expression of these cytokines.
The T/C genotype of TGFB1 codon10, considered a high
cytokine producer [24], was a risk factor for patients treated
with R-CHOP to evolve into a worse prognosis. TGF-β1 is
a multifunctional anti-inflammatory cytokine that partici-
pates in different physiological situations, including cell cycle
control, hematopoiesis control, cell differentiation, angiogen-
esis, induction of apoptosis, and cell matrix formation [25].
In the NHL, the expression of this cytokine is associated with
more aggressive lymphomas [9] and, the high-producing
genotype of this cytokine was associated with unfavorable
prognoses [24].
As our control group consisted of voluntary blood
and bone marrow donors with maximum age of 60 years,
it was not possible to match the patients and controls by
age, considering that DLBCL mainly affects individuals
after the age of 60. We acknowledge that this may indi-
cate a flaw in our study, and in order to decrease the
bias, we did the logistic regression test adjusted for age
and gender.
Generally speaking, genotypes associated with lower pro-
duction or intermediate production of IL-10 and increased
production of IFN-γ were associated with the protection for
the development of the DLBCL, possibly favoring the Th1
immune response and diminishing the cell proliferation
capacity. However, patients receiving the R-CHOP treatment
presented unfavorable prognoses in the presence of geno-
types related to the intermediate production of IL-10 and
high production of TGF-β1, indicating that cytokines may
be related to response to treatment and action mechanisms
of Rituximab. To confirm these findings, further studies with
a larger number of samples are required. It should be noted
that in our study, patients were well characterized and
followed up during treatment. During the study period, all
the individuals who presented the diagnosis of DLBCL and
who agreed to participate in the study constituted our
sample.
The results of this study indicate that polymorphisms in
certain cytokine genes may favor the development of DLBCL
and may indicate a better or worse prognosis in patients
treated with R-CHOP.
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